Atropine-induced toxicity after off-label sublingual administration of eyedrop for sialorrhoea treatment in neurological disabled patients.
atropine
pharmacokinetics
sialorrhoea
sublingual route
toxicity
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
12
01
2021
received:
12
10
2020
accepted:
20
01
2021
pubmed:
2
2
2021
medline:
28
10
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
Sialorrhea is a troublesome and disabling symptom defined by the unintentional loss of saliva from the mouth, usually associated with swallowing disorders. Today there is no consensus about the management of sialorrhoea, but off-label use of ophthalmic atropine eyedrop administered sublingually may offer benefits, despite limited safety data. We report 2 cases of atropine overdose after sublingual administration illustrating that atropine can expose to severe adverse effects when administered sublingually. The noncompartmental pharmacokinetic study of atropine performed in 1 patient highlighted that systemic absorption of sublingual atropine was effective (C
Substances chimiques
Ophthalmic Solutions
0
Atropine
7C0697DR9I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3364-3369Informations de copyright
© 2021 British Pharmacological Society.
Références
Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis. 2019;9:19-26.
Norderyd J, Graf J, Marcusson A, et al. Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study. Int J Paediatr Dent. 2017;27(1):22-29.
Young CA, Ellis C, Johnson J, Sathasivam S, Pih N. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (Review). Cochrane Database Syst Rev. 2011;5:1-19.
Rapoport A. Sublingual atropine drops for the treatment of pediatric sialorrhea. J Pain Symptom Manage. 2010;40(5):783-788.
Scofano Dias BL, Fernandes AR, Maia Filho HD. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Arq Neuropsiquiatr. 2017;75(5):282-287.
Azapağası E, Kendirli T, Perk O, et al. Sublingual Atropine Sulfate Use for Sialorrhea in Pediatric Patients. J Pediatr Intensive Care. 2020;9(3):196-200.
Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: A review of the etiology and management options. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodoncia. 2006;101(1):48-57.
Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982-e1991.
Mato A, Limeres J, Tomás I, et al. Management of drooling in disabled patients with scopolamine patches. Br J Clin Pharmacol. 2010;69(6):684-688.
Steffen A, Jost W, Bäumer T, et al. Hypersalivation: update of the German S2k guideline (AWMF) in short form. J Neural Transm. 2019;126(7):853-862.
Duguès P, Fabresse N, Megarbane B, Alvarez JC, Larabi IA. Validation of an LC-MS/MS method for the quantification of seven angiotensin converting enzyme inhibitors (ACE) and three active metabolites in plasma by LC-MS/MS. Application to a toxicokinetic study of ramipril and perindopril acute poisonings. Toxicol Anal Clin. 2020;32(1):12-22. https://doi.org/10.1016/j.toxac.2019.08.001
Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 12th ed. Foster City: Atropine; 185-187.
Taylor D, Paton CKS. The Maudsley Prescribing Guidelines in Psychiatry. 13th ed. Oxford: Wiley-Blackwell; 2018.
Guideline & Protocols advisory Committe. BCGuideline.ca. Appendix A: Medications Used in Palliative Care for Dyspnea and Respiratory Secretions. 2017.
Dias BL, Fernandes AR, Maia Filho HS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J). 2016;92(6):549-558.
Staffieri P, Owusu K, Cardinale M, Castel A. Ophthalmic atropine for sublingual use: A novel treatment for excessive respiratory secretions. Case Reports Intern Med. 2016;3(3):82-86. https://doi.org/10.5430/crim.v3n3p82
Matos Santana TE, Capurso NA, Ranganathan M, Yoon G. Sublingual atropine in the treatment of clozapine-induced sialorrhea. Schizophr Res. 2017;182:144-145.
Rajpal S, Ali R, Bhatnagar A, Bhandari SK, Mittal G. Clinical and bioavailability studies of sublingually administered atropine sulfate. Am J Emerg Med. 2010;28(2):143-150. https://doi.org/10.1016/j.ajem.2008.10.025
Lahdes K, Kaila T, Huupponen R, Salminen L, Iisalo E. Systemic absorption of topically applied ocular atropine. Clin Pharmacol Ther. 1988;44(3):310-314.
Gervais HW, El Gindi M, Radermacher PR, et al. Plasma concentration following oral and intramuscular atropine in children and their clinical effects. Paediatr Anaesth Published Online First. 1997;7(1):13-18. https://doi.org/10.1046/j.1460-9592.1997.d01-40.x
Kanto J, Klotz U. Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Acta Anaesthesiol Scand. 1988;32(2):69-78.
Berghem L, Bergman U, Schildt B, Sörbo B. Plasma atropine concentrations determined by radioimmunoassay after single-dose I.V. and I.M. administration. Br J Anaesth. 1980;52(6):597-601.
German E, Siddiqui N. Atropine Toxicity from Eyedrops. N Engl J Med. 1970;282(12):689.
Drogrey M, Merle F, Levraut J. Criminal atropine poisoning. Ann françaises médecine d'urgence. 2017;7(3):201-204.
National Agency for Medicine and Health Products. ATROPINE 1 POUR CENT FAURE, collyre en solution en récipient unidose - Summary of Product Characteristics. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=61001686&typedoc=R. Published 2019. (Accessed December 20, 2020)